entertainment -WSS

entertainment

author：knowledge 2025-10-01 20:14:35 - browse：12814

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： How to make AI work for medicine

WSS

Health officials lay out plans to cope with respiratory virus season

Kellogg’s is going to war over Mexico’s nutrition label rules

People can get long Covid without testing positive for virus: Study

Why more medical students aren't specializing in primary care

California store owner shot dead in dispute over displaying Pride flag: Police

Feds fine Medicare Advantage plans for overcharging members

Wikipedia

entertainment

entertainment

Psychedelics group wrestles with new pharma identity

Republicans love RFK Jr. What's that tell us about health in 2024?

Wildfire smoke exposes gaps in outdoor worker protections

Health officials lay out plans to cope with respiratory virus season

State Dept. review finds Biden bears some blame for Afghanistan failures

AstraZeneca challenges Medicare drug negotiation program

Psychedelics group wrestles with new pharma identity

Feds fine Medicare Advantage plans for overcharging members

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

In science, is the line between industry and academia shifting?

leisure time

Complete sequence of Y chromosome published for first time

CDC says it’s too soon to assess risk posed by Covid subvariant

Feds fine Medicare Advantage plans for overcharging members

Departing Stanford president retracts two papers

How the first Native Hawaiian psychiatrist helped diversify medicine

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

knowledge

hotspot

hotspot

knowledge